Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT.

Ann Rheum Dis. 2005 May;64(5):699-703. Epub 2005 Feb 4.

2.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
3.

Rheumatoid arthritis and malignant lymphomas.

Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L.

Curr Opin Rheumatol. 2004 May;16(3):254-61. Review.

PMID:
15103253
4.

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ.

Ann Rheum Dis. 2009 Jul;68(7):1177-83. doi: 10.1136/ard.2008.094904. Epub 2008 Nov 19. Review.

PMID:
19019889
5.

Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.

Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, Mariette X, Coenen MJ.

Ann Rheum Dis. 2010 Jun;69(6):1022-8. doi: 10.1136/ard.2009.117622. Epub 2009 Dec 4. Review.

PMID:
19966089
6.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

7.

Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.

Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J.

Br J Dermatol. 2007 Feb;156(2):368-71. Review.

PMID:
17223880
8.

Anti-TNF therapy: safety aspects of taking the risk.

Rosenblum H, Amital H.

Autoimmun Rev. 2011 Jul;10(9):563-8. doi: 10.1016/j.autrev.2011.04.010. Epub 2011 May 5. Review.

PMID:
21570495
9.

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE.

Semin Arthritis Rheum. 2005 Jun;34(6):819-36. Review.

PMID:
15942917
10.

[TNFalpha blockers and infectious risk in rheumatoid arthritis].

Raffeiner B, Botsios C, Ometto F, Bernardi L, Montante A, Sfriso P, Todesco S, Punzi L.

Reumatismo. 2009 Jul-Sep;61(3):165-73. Review. Italian.

11.

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.

Barnabe C, Martin BJ, Ghali WA.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):522-9. doi: 10.1002/acr.20371. Review.

12.

Management of rheumatoid arthritis.

Handa R.

Natl Med J India. 2004 May-Jun;17(3):143-51. Review.

PMID:
15253402
13.

Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Symmons DP, Silman AJ.

Arthritis Rheum. 2004 Jun;50(6):1703-6. Review. No abstract available.

14.

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate.

Bologna C, Picot MC, Jorgensen C, Viu P, Verdier R, Sany J.

Ann Rheum Dis. 1997 Feb;56(2):97-102. Review.

15.

[Induction of malignant neoplasm].

Tohma S.

Nihon Rinsho. 2007 Jul;65(7):1321-6. Review. Japanese.

PMID:
17642250
16.

Side effects of anti-TNF therapy: current knowledge.

Antoni C, Braun J.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S152-7. Review.

PMID:
12463468
17.

Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.

Franklin JP, Symmons DP, Silman AJ.

Ann Rheum Dis. 2005 May;64(5):657-8. Review. No abstract available.

18.

Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?

Lakatos PL, Miheller P.

Curr Drug Targets. 2010 Feb;11(2):179-86. Review.

PMID:
20210767
19.

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis.

Che H, Lukas C, Morel J, Combe B.

Joint Bone Spine. 2014 May;81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7. Review.

PMID:
23932722
20.

Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis.

Katikireddi VS, Whittle SL, Hill CL.

Int J Rheum Dis. 2010 Feb 1;13(1):12-26. doi: 10.1111/j.1756-185X.2009.01457.x. Review.

PMID:
20374381

Supplemental Content

Support Center